Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
AstraZeneca’s TRUQAP (New Molecule Capivasertib) in combination with Faslodex (Fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive breast cancer. Truqap is film coated tablets 160mg / 200mg strength administered orally.
Leave a Comment
You must be logged in to post a comment.